Skip to main content

MoonLake Immunotherapeutics

corporate_fare Company Profile

MoonLake Immunotherapeutics

MLTX·NASDAQ·Life Sciences·CIK 0001821586

MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases. The company is currently a single asset company, concentrating on the development of SLK. SLK is a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, exclusively licensed from MHKDG. This Nanobody has shown potential, based on response levels in clinical trials, to modify disease in dermatology and rheumatology patients. SLK is a proprietary Nanobody discovered by Ablynx N.V., Belgium, a Sanofi company, and was previously studied by MHKDG and Avillion LLP under a 2017 co-development agreement. Nanobodies are registered trademarks of Ablynx. These Nanobodies can selectively bind to specific antigens with high affinity and have a fraction of the molecular weight of traditional antibodies. They offer advantages over traditional monoclonal antibodies, including the potential to create multivalent molecules with enhanced ability to penetrate inflamed tissue, especially with an additional albumin binding domain like SLK, an easier manufacturing process, and higher thermostability. MoonLake Immunotherapeutics is developing SLK for inflammatory diseases in dermatology and rheumatology where IL-17A and IL-17F are known to drive the pathophysiology. Current target diseases include hidradenitis suppurativa (HS), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), palmoplantar pustulosis (PPP), and other inflammatory conditions such as psoriasis (PsO). These target diseases affect millions of people worldwide.

MoonLake Immunotherapeutics (NASDAQ:MLTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for MLTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for MLTX spans 10-Q, 8-K, 424B5.

Recent high-impact activity:

  • IZAR-1 Hits Week 16 Endpoints; Q3 Loss Wider Than Expected at $0.93/Share
  • MoonLake 10-Q: $498.5M Cash to Mid-2028, Q3 Net Loss $79.5M, 85.1M Shares Out
  • MoonLake Q3: $498.5M Cash, BLA Acceptance Decision Due by End-November
  • MoonLake Submits BLA to FDA for Sonelokimab in Hidradenitis Suppurativa
  • MoonLake's Psoriatic Arthritis Drug Hits Endpoints, But Stock Drops 6%

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$227.32M
Diluted EPS
-$3.53
Op. Cash Flow
-$196.01M
Free Cash Flow
-$196.04M
Operating Income
-$244.83M
Cash & Equivalents
$334.52M
Total Debt
$74.1M
Debt / Equity
0.24×
Shares Outstanding
64.46M sh
Source: 10-K · filed 2026-02-25 · accession 0001821586-26-000002

Short Interest & Short Volume

2.85 days to cover

FINRA reported short interest of 5,473,842 shares in MLTX as of the October 30, 2026 settlement, a 30.1% decrease from the prior period — about 2.9 days to cover at its recent average daily volume. On November 20, 2026, 58.9% of MLTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,473,842 shares as of October 30, 2026
Change vs prior period▼ 30.1%
Days to cover2.85 at avg daily volume of 1,918,072
Daily short volume (FINRA facilities)58.9% of 761,602 shares on November 20, 2026
5-day average short volume57.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for MLTX, detected from its recent SEC filings · based on capital-structure filings through 2026-08-10.

1 recent capital raiseATM program1 shelf registration

Offering Priced and Finalized · Significant Capital Raise

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with M →
$11.07
52-week range · as of 2026-11-04 $9.46 – $23.29
Market cap
$942.13M
Volume
1.7M (1.1× avg)
3-mo avg 1.6M
Live data · 2026-11-21 14:16 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MLTX - Latest Insights

MLTX
Nov 09, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $11.60
Real-time Price: $11.07 info
Change: -$0.530 (-5%) info
Market Cap: $942.131M info
MLTX
Nov 04, 2026, 7:10 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.62
Real-time Price: $11.07 info
Change: -$0.550 (-5%) info
Market Cap: $942.131M info
MLTX
Nov 04, 2026, 7:07 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.61
Real-time Price: $11.07 info
Change: -$0.540 (-5%) info
Market Cap: $942.131M info
MLTX
Sep 30, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.81
Real-time Price: $11.07 info
Change: -$0.7407 (-6%) info
Market Cap: $942.131M info
MLTX
Aug 10, 2026, 1:21 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $17.11
Real-time Price: $11.07 info
Change: -$6.04 (-35%) info
Market Cap: $942.131M info
MLTX
Aug 10, 2026, 7:46 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $16.19
Real-time Price: $11.07 info
Change: -$5.12 (-32%) info
Market Cap: $942.131M info
MLTX
Aug 10, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $18.64
Real-time Price: $11.07 info
Change: -$7.57 (-41%) info
Market Cap: $942.131M info
MLTX
Aug 10, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $18.90
Real-time Price: $11.07 info
Change: -$7.83 (-41%) info
Market Cap: $942.131M info
MLTX
Jul 14, 2026, 5:31 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.59
Real-time Price: $11.07 info
Change: -$9.52 (-46%) info
Market Cap: $942.131M info
MLTX
Jun 25, 2026, 6:23 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $19.95
Real-time Price: $11.07 info
Change: -$8.88 (-45%) info
Market Cap: $942.131M info
MLTX
Jun 25, 2026, 6:18 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $19.95
Real-time Price: $11.07 info
Change: -$8.88 (-45%) info
Market Cap: $942.131M info
MLTX
Jun 24, 2026, 5:20 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $19.72
Real-time Price: $11.07 info
Change: -$8.65 (-44%) info
Market Cap: $942.131M info
MLTX
Jun 23, 2026, 11:09 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $21.25
Real-time Price: $11.07 info
Change: -$10.18 (-48%) info
Market Cap: $942.131M info
MLTX
Jun 22, 2026, 5:25 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $21.24
Real-time Price: $11.07 info
Change: -$10.17 (-48%) info
Market Cap: $942.131M info
MLTX
Jun 22, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $20.70
Real-time Price: $11.07 info
Change: -$9.63 (-47%) info
Market Cap: $942.131M info
MLTX
Jun 22, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $22.93
Real-time Price: $11.07 info
Change: -$11.86 (-52%) info
Market Cap: $942.131M info
MLTX
Jun 09, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $17.71
Real-time Price: $11.07 info
Change: -$6.64 (-37%) info
Market Cap: $942.131M info
MLTX
Jun 01, 2026, 6:23 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $18.68
Real-time Price: $11.07 info
Change: -$7.61 (-41%) info
Market Cap: $942.131M info
MLTX
Jun 01, 2026, 6:20 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.68
Real-time Price: $11.07 info
Change: -$7.61 (-41%) info
Market Cap: $942.131M info
MLTX
May 11, 2026, 8:55 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $18.20
Real-time Price: $11.07 info
Change: -$7.13 (-39%) info
Market Cap: $942.131M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets